In vivo / preclinical – Anti-infectives
In vivo services to find the next generation drugs that combat infectious disease
With the rising prevalence of drug-resistant microorganisms, effective and potent anti-infective agents are becoming increasingly more relevant in order to treat infectious diseases. Eurofins Pharma Discovery Services identified this need over 30 years ago and has since been working diligently with the pharmaceutical industry to provide a robust portfolio of in vitro and in vivo Anti-infective models to support the discovery and development of novel antimicrobial therapies.
The broad portfolio at Eurofins contains over 50 validated models used to evaluate the efficacy of your drug candidates. Our validated methods are optimized for minimal data scatter and are demonstrated dose-responsive to standard antimicrobial agents. The models have been used to test small molecules, drug combinations, biologics, RNAi, liposomal formulations, nanoparticles, and vaccines.
Features of in vivo Anti-infective services from Eurofins: